Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Aspirin
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 68 results found since Jan 2013.
Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke
Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear. We sought to investigate the relationship between antecedent aspirin use and stroke severity in patients presenting with acute ischemic stroke (AIS).
Source: Journal of Stroke and Cerebrovascular Diseases - July 17, 2016 Category: Neurology Authors: Sarah Nelson, Lisa Cloonan, Allison S. Kanakis, Kaitlin M. Fitzpatrick, Kelsey I. Shideler, Adriana S. Perilla, Karen L. Furie, Natalia S. Rost Source Type: research
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response
Antiplatelet therapy is a cornerstone prevention strategy for secondary ischemic stroke (IS) and transient ischemic attack (TIA). Yet, a proportion of patients who receive antiplatelet therapy experience recurrent ischemic cerebrovascular events. A recent meta-analysis found an increased risk of recurrent stroke in clopidogrel- or aspirin-treated patients with ischemic stroke who had high on-treatment platelet reactivity (HTPR). Few studies have focused specifically on clopidogrel HTPR. Therefore, the aim of this study was to examine the relationship between clopidogrel HTPR and recurrent ischemic events in a population of...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2018 Category: Neurology Authors: Charlotte L ützhøft Rath, Niklas Rye Jørgensen, Troels Wienecke Source Type: research
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial
Background: Embolic stroke of undetermined source (ESUS) identifies patients with cryptogenic ischemic stroke presumed due to embolism from several unidentified sources. Among patients with recent ESUS, we sought to determine independent predictors of recurrent ischemic stroke during treatment with aspirin or rivaroxaban and to assess the relative effects of these treatments according to risk. Methods: Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 f...
Source: Journal of Stroke and Cerebrovascular Diseases - May 30, 2019 Category: Neurology Authors: Robert G. Hart, Roland C. Veltkamp, Patrick Sheridan, Mukul Sharma, Scott E. Kasner, Shrikant I. Bangdiwala, George Ntaios, Ashkan Shoamanesh, Sebastian F. Ameriso, Danilo Toni, Anna Czlonkowska, Arne Lindgren, Graeme J. Hankey, Kanjana. S. Perera, Ashfaq Source Type: research
Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke
This study aimed to identify factors that may affect platelet aggregability and their role in clinical outcomes in acute ischemic stroke. Methods: Consecutive acute ischemic stroke patients (n = 352) who were transferred within 24 hours after its onset were enrolled. Peripheral venous blood was sampled to measure platelet aggregability and other parameters. Results: Mean values of spontaneous small-sized platelet aggregates and collagen- or adenosine diphosphate (ADP)-induced large-s ized aggregates were elevated in acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - June 3, 2019 Category: Neurology Authors: Kaho Harima, Sumika Honda, Kasumi Mikami, Maiko Kitajima, Mayumi Urushizaka, Toshiko Tomisawa, Joji Hagii, Hirofumi Metoki, Minoru Yasujima, Tomohiro Osanai Source Type: research
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis
Cilostazol has promise as an alternative to aspirin for secondary stroke prevention given its vasodilatory and anti-inflammatory properties in addition to platelet aggregation inhibition. We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA).
Source: Journal of Stroke and Cerebrovascular Diseases - December 31, 2020 Category: Neurology Authors: Michelle P. Lin, James F. Meschia, Neethu Gopal, Kevin M. Barrett, Owen A. Ross, Nil üfer Ertekin-Taner, Thomas G. Brott Source Type: research
Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen
This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day). Platelet function was measured using 3 different “point-of-care” platelet function analyzers: the Thrombelastograph hemostasis system, the Accumetrics VerifyNow system, and the Chronolog 570VS impedance aggregometer. Platelet function was assessed before administration of a 300-mg CPG loading dose and again at 26 hours and 64 hours after this loading dose along with a 75-mg daily maintenance dose. All 3 instruments detected marked ...
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2011 Category: Neurology Authors: Zohara Sternberg, Marilou Ching, Robert N. Sawyer, Trevor Chichelli, Fan Li, David Janicke, Vladan Radovic, Bijal Mehta, Osman Farooq, Frederick E. Munschauer Tags: Original Articles Source Type: research
Comparison of Aspirin Response Measured by Urinary 11-Dehydrothromboxane B2 and VerifyNow Aspirin Assay in Patients with Ischemic Stroke
Conclusions: Our research confirmed poor correlation and lack of agreement between the 2 tests. Only aspirin nonresponders who were diagnosed by dTXB2 measurement were related to having cardiovascular events and death. Further research is still needed to identify the best method of diagnosis of aspirin nonresponders.
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2013 Category: Neurology Authors: Pornpatr A. Dharmasaroja, Suvaraporn Sae-Lim Tags: Original Articles Source Type: research
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes
The objective of this study was to compare the effectiveness of different loading doses of aspirin in acute ischemic stroke presenting within 48 hours of symptom onset.
Source: Journal of Stroke and Cerebrovascular Diseases - July 3, 2016 Category: Neurology Authors: Tse-Hsuan Su, Yi-Ling Chan, Jiann-Der Lee, Meng Lee, Leng-Chieh Lin, Yu-Wen Wen, Tsong-Hai Lee Source Type: research
Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke
We report a patient with an active SLE flare who presented with a recurrent ischemic stroke and was found to have numerous unruptured fusiform and saccular aneurysms in multiple vascular territories. He was treated with high-dose steroid and rituximab along with aspirin and blood pressure control for stroke prevention.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2017 Category: Neurology Authors: Shahram Majidi, Christopher R. Leon Guerrero, Shreya Gandhy, Kathleen M. Burger, Dimitri Sigounas Tags: Case Studies Source Type: research
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke
Background: To explore the association of platelet activation markers, vitamin D, and antiplatelet drugs resistance in ischemic stroke patients. Methods: A total of 230 patients with ischemic stroke were enrolled in this study. Platelet aggregation, platelet activation marker (CD62p), and vitamin D were measured after 7-14 days of dual antiplatelet treatment (aspirin + clopidogrel). All individuals were divided into a drug resistance group and a drug sensitive group according to the platelet maximum aggregation rate induced by antagonist adenosine diphosphate or arachidonic acid.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2019 Category: Neurology Authors: Bi-Chao Lu, Xiao-Jie Shi, Lin Liang, Na Dong, Zhi-Zhong Liu Source Type: research
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke
The REDUCE study demonstrated a reduction in the risk of recurrent stroke with patent foramen ovale closure and antiplatelet therapy compared to antiplatelet therapy alone. The clinicians were allowed to choose among aspirin, clopidogrel, or aspirin/dipyridamole with the expectation that all antiplatelet therapies would have similar efficacy in this population. We tested that presumption by comparing recurrent stroke rates among antiplatelet agents within the control arm of the trial.
Source: Journal of Stroke and Cerebrovascular Diseases - February 6, 2020 Category: Neurology Authors: Scott E. Kasner, Bryan Randall, Grethe Andersen, Helle K. Iversen, Risto Roine, Christina Sjostrand, John F. Rhodes, Lars S øndergaard, The Gore REDUCE Study Investigators Source Type: research
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial
The effect of interventions on functional impairment is an important outcome in stroke prevention trials and should be considered as an adjunct to counting discrete events. In the NAVIGATE-ESUS trial, 7213 patients with recent embolic strokes of undetermined source were randomized to rivaroxaban (15 mg once daily) or aspirin (100 mg daily). After 11 months there was no effect on the prevention of recurrent stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 12, 2022 Category: Neurology Authors: Jackie Bosch, Lesly A. Pearce, Mukul Sharma, Michelle Canavan, William N. Whiteley, Robert Mikul ík, Hardi Mundl, Salim Yusuf, Robert G. Hart, Martin J. O'Donnell Source Type: research
Assessment of Platelet Function in Acute Ischemic Stroke Patients Previously Treated with Aspirin
Platelet inhibition measured by platelet function tests could be critical to understand the reasons for early recurrence and to guide therapeutic recommendations. We assess the platelet function during the acute phase of ischemic stroke in patients pretreated with aspirin who continue their treatment with aspirin only, are started on clopidogrel only, or add clopidogrel to aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - October 16, 2014 Category: Neurology Authors: Aida Lago, Vera Parkhutik, Jose Ignacio Tembl, Juana Vallés, Maria Teresa Santos, Antonio Moscardó Source Type: research
